Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874794 · ClinicalTrials.gov registry record · Phase 4
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 465
- Enrollment target
NCT02874794: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.
NCT02874794 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 465 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02874794, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 465 participants
- Enrollment target
Study Summary
To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction \[LVEF\] ≤ 40%) after 12 weeks of treatment. The primary endpoint is the change in aortic characteristic impedance (Zc = dP/dQ in early systole) between baseline and Week 12.
Primary Outcome
Aortic characteristic impedance, Zc, is the ratio of the change in pressure (dP)produced by a given change in flow (dQ) in early systole, i.e., Zc = dP/dQ. Zc is related directly to aortic wall stiffness and inversely to lumen area.
Interventions
- DRUG Enalapril
- DRUG Placebo of LCZ696
- DRUG LCZ696 (sacubitril/valsartan)
- DRUG Placebo of Enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2019-01-26 |
| Phase | Phase 4 |
What the finished NCT02874794 record still lists
NCT02874794 is an interventional study that assigns participants to a tested intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 4 interventions - of which Enalapril is the first listed.
NCT02874794 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02874794 about?
NCT02874794 is a clinical study titled "Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction". To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction \[LVEF\] ≤ 40%) after 12 weeks of treatment. The primary endpo...
What is the current status of trial NCT02874794?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 465 participants. The study started on 2016-08-17. Estimated completion is 2019-01-26.
What interventions are being tested in trial NCT02874794?
The interventions under investigation include: Enalapril (DRUG), Placebo of LCZ696 (DRUG), LCZ696 (sacubitril/valsartan) (DRUG), Placebo of Enalapril (DRUG).
Who is sponsoring clinical trial NCT02874794?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02874794's enrollment target sits among peer trials
465 182nd of 2000 higher than 1,818 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717698 · 465 participants · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- NCT07420283 · 465 participants · Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI